Drug-eluting stents vs. bare metal stents in patients with cardiogenic shock: A comparison by propensity score analysis

Journal of Cardiovascular Medicine

Volumn 16, Issue 3, 2015, Pages 220-229

  Jaguszewski, Milosz ^a   Ghadri, Jelena Rima ^a   Seifert, Burkhardt ^b   Hiestand, Thierry ^a   Herrera, Paola ^a   Gaemperli, Oliver ^a   Landmesser, Ulf ^a   Maier, Willibald ^a   Nallamothu, Brahmajee K ^c   Windecker, Stephan ^d   Lüscher, Thomas F ^a   Templin, Christian ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bare metal stent; Cardiogenic shock; Drug eluting stent; Propensity score analysis

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BARE METAL STENT; BIOLIMUS ELUTING STENT; CARDIOGENIC SHOCK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PACLITAXEL ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; REVASCULARIZATION; SIROLIMUS ELUTING STENT; STENT THROMBOSIS; TACROLIMUS ELUTING STENT; ZOTAROLIMUS ELUTING STENT; COMPARATIVE STUDY; DEVICES; MIDDLE AGED; RETROSPECTIVE STUDY; SHOCK, CARDIOGENIC; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; TREATMENT OUTCOME;

EID: 84925882181     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000106     Document Type: Article

References (28)

1. Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999;340:1162-1168.
2. Westaby S, Kharbanda R, Banning AP. Cardiogenic shock in ACS. Part 1: prediction, presentation and medical therapy. Nat Rev Cardiol 2012;9:158-171.
3. Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005;294:448-454.
4. Dauerman HL, Goldberg RJ, White K, et al. Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002;90:838-842.
5. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. Shock investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999;341:625-634.
6. Westaby S, Anastasiadis K, Wieselthaler GM. Cardiogenic shock in ACS. Part 2: role of mechanical circulatory support. Nat Rev Cardiol 2012;9:195-208.
7. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-1959.
8. Brar SS, Leon MB, Stone GW, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 2009;53:1677-1689.
9. Raber L, Kelbaek H, Ostoijc M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the comfortable AMI randomized trial. JAMA 2012;308:777-787.
10. Sleeper LA, Reynolds HR, White HD, et al. A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the shock trial and registry. Am Heart J 2010;160:443-450.
11. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and longterm survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006;295:2511-2515.
12. Champion S, Gauzere BA, Lefor Y. Drug-eluting stents should not be used in ST-elevated myocardial infarction with cardiogenic shock. Arch Intern Med 2012;172:1613-1614.
13. Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010;363:2310-2319.
14. De Boer SP, Lenzen MJ, Oemrawsingh RM, et al. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with nonparticipants. Eur Heart J 2011;32:2161-2167.
15. Sigwart U. Drug-eluting stents are safe and effective: right or wrong? J Am Coll Cardiol 2006;47:1361-1362.
16. Colombo A, Corbett SJ. Drug-eluting stent thrombosis: increasingly recognized but too frequently overemphasized. J Am Coll Cardiol 2006;48:203-205.
17. Lee TH, Hillis LD, Nabel EG. CABG vs. stenting: clinical implications of the SYNTAX trial. N Engl J Med 2009;360:e10.
18. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-2733.
19. Palmerini T, Genereux P, Caixeta A, et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (acute catheterization and urgent intervention triage strategy) trial. J Am Coll Cardiol 2011;57:2389-2397.
20. Maier W, Altwegg LA, Corti R, et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005;111:1355-1361.
21. Wyss CA, Neidhart M, Altwegg L, et al. Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J 2010;31:1457-1469.
22. Okamura T, Onuma Y, Garcia-Garcia HM, et al. 3-dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification. JACC Cardiovasc Interv 2010;3:836-844.
23. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-678.
24. Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol 2007;50:573-583.
25. Kalesan B, Pilgrim T, Heinimann K, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:977-987.
26. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents vs. durable polymer sirolimuseluting stents in patients with coronary artery disease (leaders):4 year followup of a randomised noninferiority trial. Lancet 2011;378:1940-1948.
27. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
28. Bradbury J. Aspirin resistance may increase death risk in some patients with heart disease. Lancet 2002;359:1128.